12 Best Small Cap Pharma Stocks to Buy Now

3. Dynavax Technologies Corporation (NASDAQ:DVAX)

Number of Hedge Fund Holders: 31

Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical company focused on developing vaccines to protect against infectious diseases. Its flagship product, Heplisav-B, is a hepatitis B vaccine for adults that offers full protection with a two-dose regimen, unlike traditional three-dose vaccines. The company uses its proprietary CpG 1018 adjuvant technology to enhance immune responses, and it generates revenue from sales of Heplisav-B and the adjuvant, which is also used in several COVID-19 vaccines. The company sells its products primarily in the U.S. and Europe.

Dynavax Technologies Corporation (NASDAQ:DVAX) reported strong Q4 2023 results, with total revenues of $72.0 million, a 30% increase from Q4 2022. The company’s flagship product, Heplisav-B, saw net product revenue of $71 million, up 39% year-over-year. It also reported a GAAP net income of $7.1 million ($0.06 per share basic) and adjusted EBITDA of $13.4 million, marking a 225% increase from the previous year.

Looking ahead, Dynavax Technologies Corporation (NASDAQ:DVAX) expects Heplisav-B revenue to reach $305 to $325 million in 2025, with plans to capture at least 60% of the market by 2030. The company is diversifying its portfolio, securing a $30 million contract with the U.S. Department of Defense for its plague vaccine program and completing enrollment for a Phase 1/2 shingles trial. These developments highlight the company’s promising pipeline and strong position in the vaccine market, which makes it an attractive investment opportunity.